Abstract
Antimicrobial resistance (AMR) represents a critical global health challenge, with methicillin-resistant Staphylococcus aureus (MRSA) posing a significant threat in both hospital-acquired and community-associated infections. Research has demonstrated that biofilm formation is a key factor contributing to drug resistance in MRSA. In this study, we investigated an fungus, Fusarium oxysporum BPF55, isolated from Blaps rynchopetera, which inhibits MRSA biofilm formation. The aim of this research was to identify the fungal strain and comprehensively characterize its genomic features, as well as to evaluate its anti-MRSA biofilm potential. Whole-genome sequencing revealed a genome size of 50,097,681 base pairs, a GC content of 47.36%, and 16,507 predicted coding genes. AntiSMASH analysis identified 56 secondary metabolite biosynthetic gene clusters, including those involved in the synthesis of various natural products such as terpenes, non-ribosomal peptides, and polyketides. Using UPLC-MS/MS, 15 compounds were annotated from the ethyl acetate extract. Molecular docking studies demonstrated that four compounds exhibit varying affinities for SarA and AgrA, two key proteins involved in MRSA biofilm formation. Overall, these findings suggest that the fungus F. oxysporum BPA55 produces a variety of secondary metabolites and contains bioactive compounds with potential anti-MRSA biofilm activity.